CR3022
An anti-corona viral monoclonal antibody.
General information
CR3022 is a human monoclonal antibody targeting the Spike protein of corona viruses. It was derived from an individual who had recovered from severe acute respiratory syndrome (SARS) infection. The virus responsible for SARS is closely related to the novel corona virus that is responsible for COVID-19 (Collins, 2020). CR3022 bound to the Spike protein prevents it is infection with the ACE2 receptor on human cells, thus blocking the viral infection. The mutations found in the Omicron variant had little effect on the binding ability between ACE2 and the monoclonal antibody CR3022 in vitro (Mader et al., 2022).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
Spike protein Spike variant Novel compound Protein factor In vitro Antibody |
Serum sample from vaccinated and unvaccinated individuals recovered from COVID-19, Expi293F™ cells | The mutations in the Omicron variant had only a minor impact on the way it binds to ACE2 and the two antibodies Sotrovimab and CR3022. |
Jun/15/2022 |
